What it's for (Indications)
- Nateglinide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- It is primarily prescribed to be taken before meals to help control postprandial glucose excursions.
- Nateglinide can be used as monotherapy, particularly in patients who have failed to achieve adequate glycemic control with diet and exercise alone and for whom metformin is contraindicated or not tolerated.
- It is also commonly used in combination therapy with other oral antidiabetic agents, such as metformin, when diet, exercise, and monotherapy with either agent do not provide adequate glycemic control.
- The primary goal of therapy with nateglinide is to reduce elevated blood glucose levels and achieve individualized target hemoglobin A1c (HbA1c) levels, thereby mitigating the long-term microvascular and macrovascular complications associated with chronic hyperglycemia in type 2 diabetes.
- This medication is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis, as its mechanism relies on residual pancreatic beta-cell function.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose of nateglinide is typically 60 mg three times daily, administered 1 to 30 minutes before each main meal. For patients who have achieved a rapid and robust glycemic response to initial therapy, or for those with a higher baseline HbA1c, a starting dose of 120 mg three times daily before meals may be considered. The maximum recommended single dose is 120 mg. Dosage adjustments should be meticulously made based on the patient's glycemic response, as assessed by regular self-monitoring of blood glucose (SMBG) and periodic hemoglobin A1c (HbA1c) measurements. It is critical for patients to understand the importance of taking nateglinide immediately prior to, or no more than 30 minutes before, a meal to optimize its effect on postprandial glucose and minimize the risk of hypoglycemia. If a meal is skipped, the corresponding dose of nateglinide should also be skipped to prevent unnecessary hypoglycemia. While specific dosage adjustments for renal or hepatic impairment are not universally defined for all stages, caution and close monitoring are warranted in these patient populations. |
Safety & Warnings
Common Side Effects
- The most common and clinically significant adverse effect associated with nateglinide therapy is hypoglycemia, which can manifest as dizziness, sweating, tremor, hunger, confusion, blurred vision, and rapid heart rate.
- The risk of hypoglycemia is increased with missed meals, insufficient food intake, increased physical activity, alcohol consumption, or concomitant use of other glucose-lowering medications.
- Patients should be thoroughly counseled on the signs and symptoms of hypoglycemia and appropriate management strategies.
- Other frequently reported side effects include upper respiratory tract infection, back pain, flu-like symptoms, headache, dizziness, diarrhea, nausea, and arthropathy.
- Less common but potentially serious adverse reactions include hypersensitivity reactions, such as rash, pruritus, and urticaria, though severe anaphylactic reactions are rare.
- Due to its mechanism of action, nateglinide's side effect profile is largely driven by its insulinotropic effects, and patients should be educated on lifestyle modifications to mitigate risks.
- Careful and regular monitoring of blood glucose levels is paramount throughout the duration of treatment to identify and manage potential adverse events.
Serious Warnings
- Black Box Warning: Nateglinide (e.g., Glytan) does **NOT** carry an FDA-mandated Black Box Warning. However, it is imperative to highlight several serious warnings and precautions for safe and effective use. The most significant safety concern associated with nateglinide is the risk of **hypoglycemia**, which can be severe and potentially life-threatening if not promptly recognized and appropriately treated. This risk is notably amplified when meals are delayed or skipped, food intake is insufficient, strenuous physical activity is undertaken without caloric adjustment, alcohol is consumed excessively, or nateglinide is used concomitantly with other glucose-lowering agents (e.g., sulfonylureas, insulin). Patients must receive thorough education on the signs and symptoms of hypoglycemia (e.g., dizziness, confusion, sweating, tremor, hunger, irritability) and be instructed on the immediate management of mild to moderate episodes with fast-acting carbohydrates. Furthermore, careful monitoring is required for patients with **hepatic impairment**, as liver dysfunction can impair nateglinide metabolism, leading to increased systemic drug exposure and a heightened potential for prolonged hypoglycemia. Nateglinide is not indicated for patients with Type 1 Diabetes or diabetic ketoacidosis, conditions where its mechanism of action would be ineffective and potentially harmful. Continuous patient education regarding diet, exercise, and blood glucose monitoring is essential to minimize these serious risks and optimize therapeutic outcomes.
- Nateglinide therapy necessitates several important warnings and precautions.
- **Hypoglycemia** is the primary and most significant risk, particularly if meals are delayed or skipped, food intake is insufficient, strenuous exercise is undertaken, alcohol is consumed in large quantities, or other glucose-lowering agents are co-administered.
- Patients must be comprehensively educated on the symptoms of hypoglycemia and appropriate corrective measures, including the consumption of fast-acting carbohydrates.
- Caution is strongly advised in patients with **hepatic impairment**, as nateglinide is extensively metabolized by the liver, and impaired liver function could lead to increased systemic drug exposure and a heightened risk of profound or prolonged hypoglycemia.
- While specific dose adjustments are not formally established for all degrees of hepatic impairment, careful monitoring of glycemic status and potential dose reduction are recommended.
- Similarly, patients with **severe renal impairment** should be managed with caution, though the parent drug clearance is not significantly altered, careful observation for any unexpected pharmacodynamic effects is prudent.
- There is a potential for **loss of glycemic control** over time, meaning that after an initial period of effectiveness, patients may require additional or alternative therapies to maintain target HbA1c levels, which is a common characteristic in the progressive nature of type 2 diabetes.
- Nateglinide should not be used in patients with type 1 diabetes or diabetic ketoacidosis due to its mechanism requiring functioning beta cells.
How it Works (Mechanism of Action)
Nateglinide is a meglitinide analog, classified as an insulin secretagogue. Its primary mechanism of action involves the rapid and short-lived stimulation of insulin release from the pancreatic beta cells. Nateglinide achieves this by binding to the sulfonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium (K_ATP) channels located on the pancreatic beta cell membrane. This binding leads to the closure of these K_ATP channels, which subsequently causes depolarization of the beta cell membrane. The depolarization, in turn, opens voltage-dependent calcium channels, facilitating an influx of extracellular calcium ions into the beta cell. The resultant increase in intracellular calcium concentration triggers the exocytosis of insulin-containing granules, leading to a rapid surge of insulin secretion. A distinguishing characteristic of nateglinide's action is its rapid onset and short duration, which enables it to specifically target and reduce postprandial glucose excursions by promptly stimulating insulin release in response to a meal. This action is glucose-dependent, meaning its insulinotropic effect is significantly diminished at lower glucose concentrations, theoretically contributing to a lower risk of hypoglycemia compared to longer-acting sulfonylureas.
Commercial Brands (Alternatives)
No other brands found for this formula.